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Abstract: Staphylococcus aureus (S. aureus) is a Gram positive bacterium that is carried 
by about one third of the general population and is responsible for common and serious 
diseases. These diseases include food poisoning and toxic shock syndrome, which are 
caused by exotoxins produced by S. aureus. Of the more than 20 Staphylococcal 
enterotoxins, SEA and SEB are the best characterized and are also regarded as 
superantigens because of their ability to bind to class II MHC molecules on antigen 
presenting cells and stimulate large populations of T cells that share variable regions on the 
 chain of the T cell receptor. The result of this massive T cell activation is a cytokine 
bolus leading to an acute toxic shock. These proteins are highly resistant to denaturation, 
which allows them to remain intact in contaminated food and trigger disease outbreaks. A 
recognized problem is the emergence of multi-drug resistant strains of S. aureus and these 
are a concern in the clinical setting as they are a common cause of antibiotic-associated 
diarrhea in hospitalized patients. In this review, we provide an overview of the current 
understanding of these proteins.  
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1. Introduction 
1.1. Source 
Staphylococcal enterotoxins are members of a family of more than 20 different staphylococcal and 
streptococcal exotoxins that are functionally related and share sequence homology. These bacterial 
proteins are known to be pyrogenic and are connected to significant human diseases that include food 
poisoning and toxic shock syndrome. These toxins are for the most part produced by 
Staphylococcus aureus (S. aureus) although other species have also been shown to be enterotoxigenic.  
S. aureus is an ubiquitous Gram-positive coccus of approximately 1 m in diameter and forms 
clusters. It colonizes humans as well as domestic animals, and is a common opportunistic pathogen. It 
is estimated that S. aureus is persistent in 20% of the general population, while another 60% are 
intermittent carriers [1]. Most frequently, the anterior nares is the site of colonization in humans, and 
this colonization increases the risk of infections when host defenses are compromised. This is 
supported by multiple observations. For instance, the frequency of infections is higher in carriers than 
in non-carriers [2]. Non-carriers commonly acquire infections through contaminated food or when 
food handlers who are carriers contaminate food during preparation. 
S. aureus is a facultative anaerobe forming yellow colonies on rich medium and causing an ,  
and double ( + hemolysis on blood agar plates [3]. It expresses a wide array of cell-associated and 
secreted virulence factors. These properties make it a versatile pathogen capable of a wide range of 
infections. The secreted factors include various enzymes, cytotoxins, exotoxins, and exfoliative toxins. 
The chief function of these enzymes is to turn host components into nutrients that the bacteria may use 
for growth. Among the other secreted factors are exotoxins that include staphylococcal enterotoxins 
(SE), and toxic shock syndrome toxin (TSST)-1 and are the focus of this review. These factors subvert 
the host immune system and illicit major responses as described below.  
Most genes coding for SEs are located on mobile elements such as plasmids, bacteriophages or 
pathogenicity islands [4,5]. Thus, horizontal transfer between strains is not rare. In fact, a recent study 
showed that most S. aureus isolates obtained from three separate hospitals had more than one 
enterotoxin gene [6]. The median number of enterotoxin genes in the S. aureus isolates in that study 
was five and some contained up to 12 enterotoxin genes [6]. Although there are more than 20 distinct 
staphylococcal enterotoxins, only a few of them have been studied in depth. The most common 
staphylococcal enterotoxins are SEA and SEB. As shown in Table 1, SEA is the most common toxin in 
staphylococcus-related food poisoning. SEB, while it is associated with food poisoning, has been 
studied for potential use as an inhaled bioweapon [7]. SED is suggested to be the the second most 
common staphylococcal toxin associated with food poisoning worldwide, and one study showed that 
only very small amounts of this toxin were needed to induce food poisoning [8]. SEE has also been 
documented in some cases of food poisoning, while SEF has been implicated in toxic shock syndrome 
[8,9]. SEG, SEH, and SEI are not as well studied as the others, but were associated with one of the 
food poisoning outbreaks in Taiwan [10]. SEH has been also identified as one of the causes of massive 
food poisoning associated with the reconstituted milk consumption in Osaka, Japan in 2000 [11].  
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Table 1. Unique features of some common SEs.  
Staphylococcal 
Enterotoxin 
Feature  Binding to Class II MHC 
SEA 
Most common toxin associated with 
staphylococcal food poisoning 
Alpha and beta chains [12] 
SEB  Studied as a biological weapon  Alpha chain [13] 
SEC  Commonly isolated from animals [14] 
Outside the binding groove on the 
flanking helix from the α chain [15] 
SED  Food poisoning [16]  Alpha and Beta chains [17] 
SEE  Food poisoning [9]  Beta chain [18] 
SEF  Associated with toxic shock syndrome [8]  Binds to alpha and beta chains [19] 
SEG  Minor role in food poisoning [10]  SEB-like interaction with a chain [20] 
SEH  Food poisoning [10,11]  Alpha chain [21] 
SEI  Minor role in food poisoning [10]  Beta chain [22] 
1.2. Structure 
Staphylococcal enterotoxins (SEs) are broadly classified as superantigens, which, as described in 
detail below, have the ability to stimulate large populations of T cells (~20–30%) leading to the 
production of a cytokine bolus [23,24]. At least 20 serologically distinct staphylococcal superantigens 
have been described that include SEs A through V and toxic shock syndrome toxin-1 (TSST-1). SEA, 
SED, and SEE share 70–90% sequence homology, while only 40–60% with SEB, SEC, and TSST-1 
[17,24].Their mature length is approximately 220–240 amino acids, depending on the toxin, and their 
molecular size is on average ~25 kD and have significant sequence variability, but when folded have 
similar three-dimensional structures [25–27].  
The three dimensional structure for multiple SEs has been determined by crystallography [28–35]. 
They are by and large elliptical in shape and have two major unequal domains composed mostly of  
strands and a few -helices. The two domains are separated by a shallow cavity. The larger of the two 
domains contains both the amino and carboxyl termini. Mutational analysis of both SEA and SEB 
implicated this cavity in the binding to T cell receptors (TcR) [36,37]. Another region on SEA 
identified by mutational analysis to interact with the TcR V 7 and 8.1 is tyrosine 66, while a stretch of 
amino acids from 45 to 58 on SEB was found to be involved in the binding to class II major 
histocompatibility complex (MHC) molecules that are expressed by antigen presenting cells (APC) 
[38]. Several of these enterotoxins have a Zn-binding site that contributes to their interaction with 
class II MHC molecules [32,33]. Studies showed that stretch of amino acids (a.a. 118–175) located two 
thirds of the length of the protein sequence is similar to the COOH-terminal end of the human and 
mouse CD74 protein (aka invariant chain) [39], which binds class II MHC molecules early during their 
synthesis in the endoplasmic reticulum and serves as a scaffold for their assembly. The most effective 
and well studied class II MHC molecule for Staphylococcal enterotoxin binding is the HLA-DR1 allele Toxins 2010, 2  
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[40]. HLA-DR has two chains, α and β, that Staphylococcal enterotoxins may bind, some bind to both 
chains, like SEA and SED, while the others bind one chain or the other as shown in Table 1. SEA has 
also been examined in binding to other class II MHC isoforms and was shown to successfully bind to 
HLA-DP and HLA-DQ. SEB and SEC failed to bind to HLA-DP, but did show some interaction with 
HLA-DQ [41]. 
1.3. Properties 
These SE proteins have a remarkable ability to resist heat and acid. Therefore, they may not be 
completely denatured by mild cooking of contaminated food. They are pyrogenic and share some other 
important properties that include the ability to induce emesis and gastroenteritis as well as their noted 
superantigenicity. They are resistant to inactivation by gastrointestinal proteases including pepsin, 
trypsin, rennin and papain [42]. Thus, they can easily outlast the bacteria that produce them.  
2. SEs in Food-Borne Poisoning Associated Diarrhea 
A frequently cited, but somewhat dated, estimate by the Centers for Disease Control (CDC) on 
food-borne diseases is that SEs affect approximately 80 million individuals in the US, alone, resulting 
in 325,000 hospitalizations and more than 5,000 deaths [43]. According to the World Health 
Organization, death of about two million individuals in the world is due to food borne diarrheal 
diseases. The economic impact of food-borne diseases is also substantial. In the US, the estimated 
costs for these diseases may reach $35 billion annually [44].  
Staphylococcal food-borne diseases acquired from eating enterotoxin-contaminated food are the 
second most commonly reported types of food-borne diseases. The high incidence of staphylococcal 
food poisoning is due to the insufficient pasteurization/decontamination of originally contaminated 
product source [45] or its contamination during preparation and handling by individuals who are 
carriers of the organism. Also, since S. aureus grows over a wide range of temperatures and pH, the 
bacteria may grow in a wide assortment of foods. Therefore, food that is contaminated with   
SE-producing strains, if left at temperatures that allow rapid growth of the bacteria (i.e., inadequate 
refrigeration) is a common source of SE-outbreaks.  
The amount of toxin needed to cause disease is less than 1 g. In an outbreak due to enterotoxin 
(SEA)-contaminated chocolate milk, the amount of toxin was reported to be only 0.5 ng/mL [46]. The 
disease has a short incubation period that ranges from just a few minutes to hours since the toxin is 
preformed. Symptoms include nausea, vomiting, abdominal pain, cramps and diarrhea. SEA is 
responsible for approximately 80% of the cases of food poisoning outbreaks in the USA, while SEB is 
responsible for 10% of the cases [47,48]. The disease is usually self-resolving, is rarely lethal and the 
elderly are more susceptible.  
3. Staphylococcal Enterotoxins in Nosocomial and Antibiotic-Associated Diarrhea 
S. aureus is a major cause of nosocomial infections and community-acquired diseases. Diarrhea is a 
frequent side effect of antibiotic treatment and is prevalent among hospitalized patients, especially 
those in geriatric wards or intensive care units. The severity of antibiotic associated diarrhea ranges Toxins 2010, 2  
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from mild to fatal, such as cases of pseudomembranous colitis. While the causative agent of   
antibiotic-associated diarrhea is not always easy to determine, S. aureus is highly suspected as it can be 
a member of the gut microflora and stools of antibiotic-associated diarrhea patients have been found to 
contain enterotoxin-producing strains of S. aureus [49]. In one study, investigators examined 
nosocomial antibiotic-associated diarrhea and found stool specimens that were positive for SEs with a 
high density of bacteria (10
8 CFU/g of stool)[50]. It is important to note that most of the   
antibiotic-associated diarrhea isolates of S. aureus are methicillin-resistant (MRSA)[50]. Methicillin is 
a semisynthetic -lactamase-insensitive -lactam. Resistance to this antibiotic is linked to the mecA 
gene that encodes a penicillin-binding protein called PBP2a, which allows the synthesis of the cell wall 
even at lethal concentrations of -lactams, because PBP2a has low affinity for -lactams [51]. MRSA 
strains are resistant to all -lactam antibiotics. Thus, MRSA represent the model multi-drug resistant 
bacterial pathogens. MRSA is a worldwide problem that has increased steadily during the last three 
decades. In 2003, 60% of S. aureus in the ICU were found to be MRSA [52]. Importantly, the majority 
of the MRSA are toxin producing strains (TSST-1, SEA, SEB, SED [53]). This multi-drug resistant 
pathogen is among the major concerns in hospitals. How the production of the toxin affect the 
immunopathogenesis of MRSA associated diarrhea remains unclear. Therefore, the better 
understanding of the role of S. aureus-associated toxins in the immunopathogenesis of MRSA 
associated nosocomial and antibiotic-associated diarrhea are required to better prevention and 
treatment of the infection caused by this ancient nemesis. 
4. Gastro-Intestinal Inflammatory Injury Associated with Enterotoxigenic Diarrheal Diseases 
The earlier studies of Gastro-Intestinal (GI) inflammatory injury associated with the SE food 
poisoning were performed in 1960–1970 using monkey and dog animal models [54–58]. It has been 
demonstrated that ingestion of SEs within food cause food poisoning, which is characterized by severe 
vomiting and diarrhea [59], as mentioned earlier. Those symptoms occur within hours after eating of  
SE-contaminated food [54]. SE food poisoning leads to inflammatory changes throughout the 
gastrointestinal tract with severe lesions in the jejunum and ileum. The direct inhibitory effect of 
purified SEs on intestinal tone, contractility and colonic transit has been noted in the dog model [56]. 
Oral and intraduodenal administration of SEA to weanling pigs was associated with increased numbers 
of lymphocytes and polymorphonuclear cells in the jejunum and duodenum, quick emetic and 
neurobehavioral responses [60], suggesting that intestine is a site of SEA action. Intragastric 
administration of a single dose of SEB to rhesus monkeys produced a lesion confined to the 
mitochondria in epithelial cells of villi and crypts and was associated with rapid infiltration of 
leukocytes to lamina propria of jejunum [55]. These changes were concomitant with the evidence of an 
acute jejunitis. Some early studies deonstrated that the administration of the enterotoxigenic 
staphyloccoccal extract into the upper ileum through isoperistaltic enterocutaneous feeding fistula 
resulted in acute ileitis in the dog model [58]. This effect was dose dependent and high doses of SEs 
resulted in the dilatation, edematous and hyperemic changes in distal ileum. Chronic administration of 
SE extract resulted in the hypertrophy of mesenteric lymph node and an increase in lymphoid 
aggregates within the ileal submucosa. Chronic administration of large dose of SE extract was 
associated with lymphoid hyperplasia in the mucosal lamina propria, submucosal fibrosis and Toxins 2010, 2  
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thickening of the bowel wall [56,58]. Mild lymphoid lesions were identified as early as 24 hrs, with 
severe lymphadenopathy, splenomegaly, and prominent Peyer's patches found at 72 hrs after 
intravenous SEB administration in the piglet model [61]. Beery et al. observed similar inflammatory 
changes in the rat stomach and duodenum even after administration of single oral dose of SEA and 
noted predominant intraepithelial lymphocytes responses in jejunum [62]. Moreover, this elegant study 
showed that the intact rat GI epithelial barrier allowed the prompt passage of orally presented SEA 
across the epithelium to the lamina propria and, subsequently, to the kidney. 
Figure 1. Model of the role of mucosal lamina professional and non professional APCs in 
SE associated Gastro-Intestinal (GI) inflammatory injury. GI inflammatory injury during 
staphylococcal enterotoxigenic disease is mediated mostly through the SE superantigenic 
effect on MHC class II expressing mucosal professional (macrophages and dendritic cells, 
DC) and non professional (such as myofibroblasts) APCs and TCR expressing CD4
+ 
T cells. SE can cross the intestinal epithelial barrier in intact form and bind to class II MHC 
molecules that expressed on subepithelial myofibroblast. These processes will lead to a 
strong production of the proinflammatory cytokines and chemokines, including IL-6, IL-8 
and MCP-1. The last one may leads to the increased chemotaxis of professional immune 
cells (CD4
+ T cells, Macrophages, DC) from gut associated lymphoid tissue (GALT) to the 
site of SE associated inflammation in GI mucosa. Those MHC class II:SEs:TCR 
interactions may in turn result in hyperactivation of the APCs and the T cells leading to the 
excessive proliferation of T cells and the uncontrolled burst of various proinflammatory 
cytokines and chemokines causing the superantigen-mediated acute inflammation and shock. 
 
Despite the significant progress in the understanding of SE associated inflammation of GI tract, it is 
still unclear how this inflammation is initiated in vivo and what is the exact role of each of the immune 
and non immune cells that contribute to the progression of the disease. Many recent ex vivo and Toxins 2010, 2  
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in vitro studies suggest that GI inflammatory injury associated with staphylococcal enterotoxigenic 
disease is mediated mostly through the SE superantigenic effect on MHC class II expressing APCs and 
CD4
+ T cells, cells expressing major receptors for SEs [63–67]. Those interactions may result in 
hyperactivation of professional as well as non-professional APCs and T cells leading to the excessive 
proliferation of CD4
+ T cells and the release of proinflammatory cytokines and chemokines that 
contribute to the SE inflammatory effect on GI tract (Figure 1)[64–68].  
5. Mechanisms of Action 
5.1. Emetic effect of SEs  
Although the superantigenic activity of SEs has been well characterized, as discussed below, the 
mechanisms behind the emetic activity are poorly understood. In large part, this is due to the dearth of 
adequate animal models, some of which were mentioned above. Non-human primates represent an 
ideal candidate, but the high costs and ethical issues prevent their use to study emetic effects of SEs. 
One animal model that seems well-suited to study the emetic response of SEs is the house musk shrew. 
This small mammal that resembles a mouse responds with vomiting two hours after peroral or 
intraperitoneal administration of SEs [69]. Studies by Hu et al., who used the house musk shrew, 
showed that the small intestine is a site of emetic action by SEA and appears to involve the   
5-hydroxytryptamine (5-HT) or serotonin pathway [70]. Serotonin is an important signaling mediator 
in the gastrointestinal tract and can activate enteric neurons, stimulate muscle responses, and enhance 
secretion. Their studies showed that SEA-induced emesis was inhibited by cannabinoid (CB) receptor 
agonists and the action was reversed by a CB1 antagonist [70]. A recent study showed that aspartic acid 
at position 227 of SEA was important in the emetic activity, since substitution of that amino acid with 
alanine resulted in a molecule devoid of emetic activity [71]. Histamine and Ca
++ channel blockers 
have also been found to prevent the emetic response to SEs suggesting an involvement of mast cells in 
enterotoxin-induced emesis.  
5.2. SE superantigenic property in immunopathogenesis associated with staphylococcal diarrheal disease 
Staphylococcal enterotoxins bind to class II MHC molecules on APCs outside of the antigenic 
peptide binding groove (Figure 2). The current literature suggests that the binding of these toxins to 
class II MHC is directed by very few residues, as shown by directed mutagenesis studies with class II 
MHC [72]. As for TSST-1, mutating a single residue may abolish its binding [73]. SEA has two 
distinct binding sites on both sides of the peptide binding groove of class II MHC. SEA molecules 
must be bound to both sites for optimal activity, which allows for class II MHC crosslinking, and 
stable interactions with T cells [70]. SED was shown to have multiple sites of interaction with class II 
MHC [17]. SEB and TSST-1 bind to the same region of HLA-DR1, but TSST-1 is the only 
staphylococcal toxin that extends part way over the peptide binding groove when bound to class II 
MHC [13]. SEE is similar structurally to SEA and binds to the same region as SEA on the beta-chain 
[18]. The SEH binding site on class II MHC overlaps with one of the SEA binding sites, and SEI binds 
to the HLA-DR1 beta-chain [21,22]. Once bound to class II MHC, SEs may then bind to T cells via the 
T cell receptor (TCR). T cells normally require presentation of a specific antigenic peptide to the TCR Toxins 2010, 2  
 
 
2184
by APCs in order to become activated. However, SEs interact with T cells in a “nonspecific” manner, 
only requiring a common variable region on the TCR (Figure 2). This MHC class II:SEs:TCR   
tri-molecular interaction leads to an uncontrolled release of various proinflammatory cytokines 
including IFN-gamma, TNF-α, IL-1β, IL-6 and IL-8, the key cytokines/chemokines causing 
superantigen-mediated acute inflammation and shock [74–77]. Whereas T cells are normally only 
activated in an antigenic specific way, their interaction with SEs leads to a massive proliferation and 
differentiation of T cells predominantly toward Th1 and Th17 phenotypes [78,79], both of which are 
associated with acute inflammatory responses.  
Figure 2. Model of SE interaction with T cell Receptors and class II MHC Molecules. The 
simultaneous binding of SEs outside of the antigen binding pocket of class II MHC on 
antigen presenting cells (APC) and to T cell receptors expressing certain V elements 
allows SEs to act as superantigens. The tripartite interaction of class II MHC:SEs:TcR 
results in the stimulation of both APC and T cells leading to the production of cytokines by 
both cell types.  
 
5.3. Effects on professional and non-professional APCs  
The intestinal epithelium is a layer of cells separating the lumen from immune cells, providing a 
barrier for the vast amount of food antigens, bacteria, and viruses to which the gut is exposed. The 
extensive inflammation induced by the immune response to SEs leads to an increase in intestinal 
epithelial permeability and a decrease in expression of tight junction proteins. Disruption of barrier 
function leads to an influx of antigens through the mucosal layer, further activating immune responses 
to these antigens as they interact with immune cells. SEs are able to cross the epithelial barrier intact 
and, by traversing this barrier, gain access to T cells. One study demonstrated that SEB was more Toxins 2010, 2  
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efficient at traversing the epithelial barrier than SEA, and thus, is more likely to reach the blood [80]. 
In addition to inducing T cell responses, SEs also induce proinflammatory responses from professional 
and non professional APCs when binding to MHC class II on these cells. In a mouse model, SEA, 
SEB, and TSST-1 were able to induce dendritic cell migration and maturation dependant on T cell 
activation [81]. Macrophages are also activated by SEs and upon binding release neutrophil 
chemotactic factors that induce neutrophil migration [82], and increased release of proinflammatory 
cytokines [83]. 
Similarly, we have shown that MHC class II-expressing intestinal subepithelial myofibroblasts, non 
professional APCs in GI mucosa, bind SEs, and are activated to produce proinflammatory cytokines 
such as IL-6, IL-8, and, to a less extent, TNF-α. Our further studies suggested that SEA was able to 
cross a monolayer of intestinal epithelial cells and bind to MHC class II expressed on isolated 
subepithelial myofibroblasts in co-culture, thus, inducing the production of MCP-1 along with the 
above mentioned proinflammatory cytokines [67]. In these studies, MCP-1 was shown to play an 
important role in the response to SEA since its neutralization decreased expression of IL-6 and IL-8 
during exposure to SEA. Moreover, the results from the same study suggest that SEA induced MCP-1 
production by the myofibroblasts might be involved in chemotaxis of lymphocytes to the site of SEA 
induced inflammation as illustrated on Figure 1. Another cell population that could bind SEs shortly 
after exposure are intestinal epithelial cells, but their class II MHC expression is prominent mostly 
during inflammation, and upon homeostasis has been distinctly observed in the duodenum [84,85]. 
When T cells were added to culture with the epithelial cell exposed to SEs, proliferation was induced 
suggesting a potential involvement of these cells in SE associated immunopathogenesis. Other studies 
have shown that interaction of the MHC class II
+ vascular endothelial cells with SEB, initiates T cell 
activation [86]. SEA interaction with these endothelial cells described to induce production of IL-8 and 
TNF-α leading to the endothelial injury [87]. Another study showed that SEA could bind to B cells via 
MHC class II molecules [88]. Collectively, these studies suggest that SEs may bind to a variety of cell 
types via MHC class II molecules and these interactions leads to their activation resulting in 
proinflammatory cytokines and chemokines production and uncontrolled activation of T cells. 
6. In Vivo Modeling of SE Associated Diarrheal Diseases 
Despite the knowledge acquired regarding the SE interactions with the host, their effect on immune 
responses, and a valid animal model of SE associated airway disease, there are only few models of  
SE-associated diarrheal disease [89–91]. Reviews of enterotoxigenic diarrheal disease models include 
very limited information about the in vivo modeling of the SE associated diarrhea [92]. The more 
susceptible animal species to develop human-like enterotoxigenic disease are non-human primate 
models, mostly using Macaca mulatta [57,93]. When introduced intragastrically, SEA and SEB have 
been shown to induce emetic responses, diarrhea and GI inflammatory changes in different Macaca spp. 
[55,68,94,95]. Kohrman et al. demonstrated that administration of TSS-associated S. aureus to 
baboons resulted in mild symptoms and was associated with decreased food intake and loose stools 
[96]. Unfortunately, the use of the primate models to study SE diarrheal disease is limited by high 
costs, short supply, and complexity of animal care. Toxins 2010, 2  
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The dog [56,58,97], pig [60] and piglet [61] models have been successfully used to reproduce some 
of the features associated with staphylococcal enterotoxigenic disease. These models have clearly 
demonstrated diarrhea and the appearance of the immunopathological changes in the gut-associated 
lymphoid tissue (GALT). However, the main disadvantage for use of those models remain similar to 
the monkey models: high cost and short supply in the available tools for the study of SE 
associated immunopathology.  
Wild strains of rodents are less susceptible to the SE or TSST-1, as the affinity of those toxins to 
murine MHC class molecules are much lower [92]. However, one of the first attempts to model SEB 
associated diarrheal disease was done in rats [98]. This model has been successfully used to study the 
effects of SEA on the GI tract [62,98]. However, an acceptable murine model to study the 
immunopathogenesis of SE-associated diarrheal disease has not yet been developed. Recent progress 
made in the development of “humanized” transgenic animals expressing the human MHC class II 
alleles, such as HLA-DR and -DQ [99] might be useful to finally get insights in the GI 
immunopathobiology of SE associated diarrheal disease.  
7. Their Potential as Agents of Biological Warfare 
SEB is the only known Staphylococcus enterotoxin that has been examined as a biological warfare 
weapon. There was particular interest in weaponizing SEB in the Cold War Era because of its stability 
and potential simplicity in production and dispersal. SEB was studied in an aerosolized form for use as 
a weapon. It may be purified from culture supernatants in the laboratory, and therefore would be easy 
to produce. As mentioned earlier, SEB is quite stable to heat, proteolytic digestion, and a wide pH 
range [7] also making it easy to produce and distribute. A very small amount (0.004 µg/kg) is effective 
at inducing symptoms, and a dose of 0.02 µg/kg could be lethal [100]. The fact that a low dose of SEB 
is sufficient to incapacitate people is another factor that makes it a potential weapon. Inhalation of SEB 
leads to shortness of breath and chest pain for several hours after exposure. With heavy exposure, more 
serious symptoms could occur such as high fever, pulmonary edema, possible acute respiratory distress 
syndrome, or septic shock [101]. Symptoms were examined in both animal studies and in several 
accidental laboratory accidents. In studies where monkeys were immunized with SEB-containing 
microspheres, all the monkeys studied developed toxic shock syndrome within 48 hours [102]. There 
have been several laboratory cases of inhalation that may represent the potential of SEB as a weapon. 
In the 1960s, three different occurrences of laboratory exposure to SEB were reported under the US 
Offensive Biological Warfare Program (http://www.cdc.gov/ncidod/EID/vol10no9/04-0250.htm 
[103]). In 1963, a total of nine people were exposed to aerosolized SEB. Two were exposed due to a 
ruptured hose in the laboratory containing SEB. Both people suffered fever, headache, gastrointestinal 
symptoms, but recovered 72 hours later. In a separate incident in 1963, five people of seven exposed 
became ill while performing experiments with monkeys. The monkeys were being exposed to 
aerosolized SEB, and it is thought the SEB was carried in the monkey’s fur, exposing laboratory 
workers while they were handling the monkeys. Within 24 hours of exposure five people experienced 
fever, cough, chest pain, diarrhea and vomiting. Four of the five people with symptoms were 
hospitalized, but all survived. The third incident of exposure during this program was in 1964 when a 
tube of aerosolized SEB meant for monkeys ruptured, resulting in the exposure of fifteen people to Toxins 2010, 2  
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SEB. Ten people developed the same symptoms as the previous two laboratory exposures and nine of 
them were hospitalized. Symptoms were cleared in three-five days. 
In addition to inhalation, SEB could be purified and introduced into water or food systems in order 
to affect large numbers of people. However, the probability of a terrorist having the technical skills to 
weaponize SEB is low. The more likely scenario is that purified SEB could be stolen from a laboratory 
so it would more likely be an isolated threat unless large amounts could be stolen. The risk of 
widespread mortality with the use of SEB as a weapon is low; however, it could effectively 
incapacitate the general population or soldiers on the front line. 
Despite its low mortality threat risk, vaccines against SEB have been examined in the 1960s and 
after the increased terrorist risks perceived after September 11th, 2001. In the 1960s, the United States 
Army Medical Research Institute of Infectious Disease (USAMARIID) focused on vaccines containing 
formalin-inactivated SEB toxin. The objective of the research was to induce protective antibodies in 
monkeys without major side effects by inactivating the toxin. In the 1960s subcutaneous injection was 
examined, and thirty years later, intramuscular injection was examined [104,105] with both leading to 
some protective responses without side effects. However, when the vaccine was administered 
intranasally it only induced weak responses. Thus, in 2003 research turned to the development of 
recombinant type of SEB vaccines. The goal for those type of vaccines is to produce a mutated SEB 
protein, which lacked its toxic property, but remains sufficiently immunogenic to induce protective 
anti-SEB immune responses [106,107].  
8. Agents that Target the Superantigen Effect of SE 
Despite all the advances in the understanding of the SE mechanism of action, the SE-associated 
diarrheal disease due to food poisoning or nosocomial S. aureus infection is of major concern in health 
programs worldwide. WHO pointed out in 2003 that the best approach to reduce the number of food 
poisoning-related disease outbreaks are preventative measures and treatments against SEs [108]. The 
preventive measures include stricter food control, hand and environmental hygiene, identification and 
isolation of carriers, and proper S. aureus antibiotic therapy [109–112].  
SE-associated diarrheal disease symptoms are abrupt, and may be severe enough to warrant 
hospitalization. Although due to the self-limitation of this disease specific anti-staphylococcal therapy 
is not always required, but it is generally agreed that antimicrobial agents with activity against 
S. aureus should be given to all patients with suspected toxic shock syndrome and MRSA infections 
[113,114]. However, the increase in MRSA strains poses a challenge to efficient therapy [111,115]. 
Therefore, novel ways targeting the prevention of SE production by S. aureus or blocking/neutralization 
of SE interaction with the host are required to ameliorate the disease outcome. SE immunopathological 
effects are strongly associated with their capacity to act as superantigens. Thus, the SE superantigenic 
properties represent a very attractive therapeutic target. Potential targets to prevent the toxic effects of 
bacterial superantigens have been well reviewed by Krakauer in 2005 [92], more recently by   
Fraeser et al. in 2008 [116], and Larkin et al. in 2009 [117]. Since the discovery of SE structures and 
immune receptors, multiple immunotherapeutic strategies have been proposed. Those strategies 
include neutralization of SEs by intravenous Ig therapy that consists of anti-SE polyclonal Abs from 
multiple donors [118–120], blocking the interaction of SEs with MHC class II or TCR [121–125], and Toxins 2010, 2  
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inhibition of signal transduction pathways activated by these superantigens, particularly NF-B  
[126–128]. The inhibition of SE-induced proinflammatory cytokine/chemokine cascade by using 
neutralizing Abs, anti-inflammatory cytokine (e.g., IL-10), or potent immunosuppressants have been 
proposed [66,67,129,130]. One study showed that doxycycline treatment inhibited human T cell 
activation and cytokine release in response to SEs and may have potential as a therapeutic strategy 
[97]. Mouse studies showed that pirfenidone, rapamycin, and dexamethasone were effective at 
blocking SEB-induced T cell proliferation and cytokine production [127]. Another recently proposed 
original approach was to use of the innate immunity modulators [128,131,132]. For instance, 
Hayworth et al. demonstrated that bovine lactoferrin was able to attenuate SEB-induced proliferation, 
IL-2 production, and CD25 expression in HLA-DR4 transgenic mouse T cells [126]. This inhibition 
was due to the lactoferrin iron-binding capacity. Dietary plasma protein supplements have been shown 
to prevent release of SEB-induced mucosal proinflammatory mediators (IFN-, TNF-, IL-6 and 
LTB4) in rats [132].  
All the available data has demonstrated that the early blockade of the mechanisms involved in the 
SE induced hyperactivation of immune responses may represent attractive strategy for the 
development of new specific anti-SE therapeutic approaches. However, more fundamental in vivo 
studies using adequate animal models are needed to understand, which of those approaches may be the 
most effective.  
9. Concluding Remarks 
SEs are members of a large family of bacterial exotoxins produced by staphylococci and 
streptococci that are functionally and structurally related. They have significant morbidity associated 
with them and are frequent as S. aureus is persistent in 20% of the general population. This population 
is considered “healthy”. Moreover, S. aureus may be transiently carried by as much as 60% of the 
population. A recognized problem is the increase in MRSA strains, which are dangerous due to their 
resistance of most antibiotics used in clinical practice. Additional work is needed to develop improved 
preventive and therapeutic strategies targeting neutralization or impairment of SE induced 
hyperactivation of the proinflammatory immune responses.  
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